Risperdal “approvable” for autism
Executive Summary
Johnson & Johnson is addressing issues outlined by FDA in a recent "approvable" letter for Risperdal for the treatment of autism. J&J filed an sNDA for Risperdal (risperidone) for use in autistic adolescents and children Dec. 19 and was granted a six-month priority review. The user fee deadline was June 19...